ALK融合基因阳性非小细胞肺癌脑转移的靶向治疗进展

Progress in targeted therapy for brain metastasis from non-small-cell lung cancer positive for ALK gene fusion

摘要: 间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）基因融合在非小细胞肺癌（non-small cell lung cancer，NSCLC）中发生率约为2%~7%，此类肺癌更易出现脑转移，严重影响患者生存质量，缩短患者的生存期。近年来，随着ALK-酪氨酸激酶抑制剂（ALK-tyrosine kinase inhibitor，ALK-TKI）的不断研发，ALK-NSCLC脑转移患者的生存期显著延长。本文对ALK-TKI治疗肺癌脑转移的研究进展进行综述，旨在为临床工作提供参考和借鉴。

Abstract: The incidence of anaplastic lymphoma kinase (ALK) gene fusion in non-small-cell lung cancer (NSCLC) is approximately 2%-7%. In cases of lung cancer with this gene mutation, the probability of brain metastasis, which seriously affects quality of life and shortens survival time, is higher. In recent years, survival time has significantly increased among ALK gene fusion-positive NSCLC patients with brain metastasis owing to continuous advances in the development of ALK-tyrosine kinase inhibitors (TKIs). This paper reviews the progress in the research on ALK-TKI use in the treatment of brain metastasis from NSCLC.